Clinical trials: Systemic AL Amyloidosis
Amyloidosis
A Safety Study of GSK3039294 in Healthy Volunteers and Patients With Systemic Amyloidosis
GSK3039294 has been developed in order to offer an orally available alternative to parenteral CPHPC (GSK2315698 [metabolite of GSK3039294]) for plasma serum amyloid P component (SAP) depletion prior to use of anti SAP monoclonal…
- Trial name
- NCT02603172
- Testing
- GSK3039294
- Where
- United Kingdom
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Amyloidosis
Study of High-Dose Melphalan and Autologous Stem Cell Transplantation in Patients With Primary Light Chain Amyloidosis
OBJECTIVES: I. Determine the response, disease-free survival, and overall survival of patients with primary light chain amyloidosis treated with high-dose melphalan and autologous stem cell transplantation. II.
- Trial name
- NCT00017680
- Testing
- Melphalan, Autologous Stem Cell Transplantation
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Herbert Irving Comprehensive Cancer Center
Systemic Amyloidosis
124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
This is a single-center, exploratory, Phase 1 Positron Emission Tomography/x-ray Computed Tomography (PET/CT) imaging study to detect amyloidosis that will enroll patients with a confirmed diagnosis of systemic amyloidosis.
- Trial name
- NCT03678259
- Testing
- 124I-p5+14 Injection
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- University of Tennessee Graduate School of Medicine
Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders
Perceptions of Burden in Patients With Late-Stage Cancer and Their Caregivers
RATIONALE: Gathering information over time about patients' sense of being a burden on their caregiver, and caregivers' sense of burden on themselves, may help doctors learn more about the desire to die in patients with late-stage…
- Conditions
- Brain and Central Nervous System Tumors, Chronic Myeloproliferative Disorders, Depression, Leukemia
- Trial name
- NCT00770419
- Testing
- medical chart review, questionnaire administration, psychosocial assessment and care
- Sponsor
- Rutgers, The State University of New Jersey
Multiple Myeloma and Plasma Cell Neoplasm
Melphalan Followed by Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and…
- Trial name
- NCT00004165
- Testing
- filgrastim, melphalan, peripheral blood stem cell transplantation
- Where
- United States
- Sponsor
- Northwestern University
Primary Systemic Amyloidosis
Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis Trial
In this study the investigators want to find out more about the addition of the antibiotic, doxycycline, to standard anti-amyloid therapy in people with amyloidosis.
- Trial name
- DUAL (NCT02207556)
- Testing
- Doxycycline
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Medical College of Wisconsin
Amorphous, Eosinophilic, and Acellular Deposit, Constipation
S1702 Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis
This phase II trial studies how well isatuximab works in treating patients with primary amyloidosis that has come back or does not respond to treatment.
- Conditions
- Amorphous, Eosinophilic, and Acellular Deposit, Constipation, Diarrhea, Early Satiety
- Trial name
- NCT03499808
- Testing
- Isatuximab, Laboratory Biomarker Analysis
- Where
- 345 sites in United States
- Volunteers
- 43 people
- Sponsor
- SWOG Cancer Research Network
Multiple Myeloma
Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic Amyloidosis
RATIONALE: Drugs used in chemotherapy, such as melphalan and dexamethasone, work in different ways to stop the growth of abnormal plasma cells, either by killing the cells or by stopping them from dividing.
- Trial name
- MRD (NCT00679367)
- Testing
- dexamethasone, lenalidomide, melphalan
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Boston Medical Center
Amyloidosis
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
The purpose of this study is to determine the safety and activity of the combination of lenalidomide with intermediate dose dexamethasone and cyclophosphamide in patients with primary systemic (AL ) amyloidosis.
- Trial name
- NCT00981708
- Testing
- Lenalidomide, Dexamethasone and Cyclophosphamide
- Where
- Greece
- Volunteers
- 37 people
- Sponsor
- University of Athens
AL Amyloidosis (AL), t(11;14) Positive
Sonrotoclax Plus Dexamethasone With or Without Daratumumab Regimen in Patients With t(11;14) Primary AL Amyloidosis
The goal of this study is to evaluate the efficacy and safety of Sonrotoclax combined Regimen in patients with t(11;14) AL amyloidosis.
- Trial name
- NCT07335887
- Testing
- sonrotoclax, Daratumumab, Dexamethasone
- Where
- 3 sites in China
- Volunteers
- 39 people
- Sponsor
- Peking University People's Hospital
Chronic Myeloproliferative Disorders, Leukemia
Combination Chemotherapy in Treating Patients With Advanced Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00003331
- Testing
- fluorouracil, leucovorin calcium, topotecan hydrochloride
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- NYU Langone Health
AL Amyloidosis
A Study on the Management and Outcome of Patients With Systemic AL Amyloidosis in Europe
This is a retrospective, observational, multicenter study to collect Real-World Evidence (RWE) data on systemic AL-AMY patients in Europe.
- Trial name
- NCT04937777
- Where
- 13 sites in Austria, Czechia and 8 more
- Volunteers
- 4,481 people
- Sponsor
- European Myeloma Network B.V.
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma or Other B-cell Cancers
RATIONALE: Peripheral stem cell transplantation may allow doctors to give higher doses of chemotherapy drugs and kill more cancer cells.
- Trial name
- NCT00003163
- Testing
- filgrastim, sargramostim, cyclophosphamide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Medical College of Wisconsin
AL Amyloidosis
Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
This is a study to determine the safety, tolerability and maximum tolerated dose of Venetoclax (ABT-199) and dexamethasone in relapsed or refractory amyloid light chain (AL) amyloidosis patients.
- Trial name
- NCT03000660
- Testing
- Venetoclax, Dexamethasone
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Tufts Medical Center
Chronic Myeloproliferative Disorders, Leukemia
Non-Ablative Allo HSCT For Hematologic Malignancies or SAA
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Peripheral stem cell transplantation may be able to replace immune cells that were destroyed by chemotherapy…
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00006379
- Testing
- anti-thymocyte globulin, graft-versus-tumor induction therapy, cyclophosphamide
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- Case Comprehensive Cancer Center
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia
Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies
This clinical trial studies fludarabine phosphate and total-body radiation followed by donor peripheral blood stem cell transplant and immunosuppression in treating patients with hematologic malignancies.
- Conditions
- Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission
- Trial name
- NCT00014235
- Testing
- fludarabine phosphate, total-body irradiation, peripheral blood stem cell transplantation
- Where
- 11 sites in United States, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Fred Hutchinson Cancer Center
Primary Systemic Amyloidosis
Lendexal in Patients With Primary Systemic Amyloidosis (AL) Newly Diagnosed
Primary outcome measure: Hematologic response rate to the association of Lenalidomide, Cyclophosphamide and Dexamethasone. Secondary outcome measures: Organ response rate.
- Trial name
- LENDEXAL (NCT01194791)
- Testing
- Lenalidomide, Cyclophosphamide, Dexamethasone
- Where
- 10 sites in Spain
- Volunteers
- 30 people
- Sponsor
- PETHEMA Foundation
Relapsed or Refractory Systemic Light Chain Amyloidosis
Study of Dexamethasone Plus IXAZOMIB (MLN9708) or Physicians Choice of Treatment in Relapsed or Refractory Systemic Light Chain (AL) Amyloidosis
The purpose of this study is to provide continued access of ixazomib and/or other study medications and to continue collecting relevant safety data to monitor participant's safety, determine whether dexamethasone plus IXAZOMIB…
- Trial name
- NCT01659658
- Testing
- IXAZOMIB, Dexamethasone, Melphalan
- Where
- 66 sites in United States, Australia and 13 more
- Volunteers
- 177 people
- Sponsor
- Millennium Pharmaceuticals, Inc.
Amyloidosis
Renal AL Amyloid Involvement and NEOD001
This is a multicenter, Phase 2b, randomized, double-blind, placebo-controlled, two-arm, parallel-group efficacy and safety study of NEOD001 as a single agent administered intravenously in adults with AL amyloidosis who have a…
- Trial name
- RAIN (NCT03168906)
- Testing
- NEOD001
- Where
- 9 sites in United States
- Volunteers
- 12 people
- Sponsor
- Tufts Medical Center
Primary Systemic Amyloidosis (AL)
Intensive Versus Conventional Treatment in Patients With Primary Amyloidosis
AL amyloidosis is caused by a clonal plasma cell dyscrasia and characterized by progressive deposition of amyloid fibrils derived from monoclonal Ig light chains, leading to multisystem organ failure and death.
- Trial name
- NCT00344526
- Testing
- Melphalan, Dexamethasone, Autologous stem cell transplantation
- Where
- 8 sites in France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Limoges